Escherichia coli Nissle 1917 Targets and Restrains Mouse B16 Melanoma and 4T1 Breast Tumors through Expression of Azurin Protein
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
Many studies have demonstrated that intravenously administered bacteria can target and proliferate in solid tumors and then quickly be released from other organs. Here, we employed the tumor-targeting property of Escherichia coli Nissle 1917 to inhibit mouse B16 melanoma and 4T1 breast tumors through the expression of azurin protein. For this purpose, recombinant azurin-expressing E. coli Nissle 1917 was developed. The levels of in vitro and in vivo azurin secretion in the engineered bacterium were determined by immunochemistry. Our results demonstrated that B16 melanoma and orthotopic 4T1 breast tumor growth were remarkably restrained and pulmonary metastasis was prevented in immunocompetent mice. It is worth noting that this therapeutic effect partially resulted from the antitumor activity of neutrophils and lymphocytes due to inflammatory responses caused by bacterial infections. No toxicity was observed in the animal during the experiments. This study indicates that E. coli Nissle 1917 could be a potential carrier to deliver antitumor drugs effectively for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, E. coli has been shown to colonize the region surrounding the necrotic core of tumors after intravenous injection9, and several reports have demonstrated the use of engineered E. coli strains to treat solid tumors in preclinical models15,62–65.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [63]
In the citing paper
“Zhang et al. developed a strain of EcN to express azurin, a small bacterial protein that induces apoptosis in tumor cells62. This engineered strain suppressed the growth of tumors and prevented pulmonary metastasis in mice63.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Probiotics, Prebiotics, and Synbiotics
de Vrese, M., & Schrezenmeir, J. (2008) · Advances in Biochemical Engineering/Biotechnology · doi:10.1007/10_2008_097 · Cited by 1,028
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614
Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
Wiemann, B., & Starnes, C. O. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90023-x · Cited by 467
Probiotics, Prebiotics and Synbiotics
Hawrelak, J. (2007) · eCite Digital Repository (University of Tasmania) · Cited by 320
Zhao, M., Yang, M., Ma, H., Li, X., Tan, X., Li, S., Yang, Z., & Hoffman, R. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0716 · Cited by 305
Bacteriolytic therapy can generate a potent immune response against experimental tumors
Agrawal, N., Bettegowda, C., Cheong, I., Geschwind, J.-F., Drake, C. G., Hipkiss, E. L., Tatsumi, M., Dang, L. H., Diaz, L. A., Pomper, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406242101 · Cited by 304
Short hairpin RNA–expressing bacteria elicit RNA interference in mammals
Xiang, S., Fruehauf, J., & Li, C. J. (2006) · Nature Biotechnology · doi:10.1038/nbt1211 · Cited by 271
Stritzker, J., Weibel, S., Hill, P. J., Oelschlaeger, T. A., Goebel, W., & Szalay, A. A. (2007) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.01.008 · Cited by 224
Henker, J., Laass, M., Blokhin, B. M., Bolbot, Y. K., Maydannik, V. G., Elze, M., Wolff, C., & Schulze, J. (2007) · European Journal of Pediatrics · doi:10.1007/s00431-007-0419-x · Cited by 199
Noncationic Peptides Obtained From Azurin Preferentially Enter Cancer Cells
Taylor, B. N., Mehta, R. R., Yamada, T., Lekmine, F., Christov, K., Chakrabarty, A. M., Green, A., Bratescu, L., Shilkaitis, A., Beattie, C. W., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2932 · Cited by 184
Cited by
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
Developing a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Leventhal, D. S., Sokolovska, A., Li, N., Plescia, C., Kolodziej, S. A., Gallant, C. W., Christmas, R., Gao, J.-R., James, M. J., Abin-Fuentes, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16602-0 · Cited by 458
Fan, J.-X., Li, Z.-H., Liu, X.-H., Zheng, D.-W., Chen, Y., & Zhang, X.-Z. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b05323 · Cited by 264
Self-citationAbouelela, M. E., & Helmy, Y. A. (2024) · Microorganisms · doi:10.3390/microorganisms12030430 · Cited by 238
“[191,192] S. Typhimurium Cancer S .”
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics
Lynch, J. P., Goers, L., & Lesser, C. F. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.02.002 · Cited by 230
He, L., Yang, H., Tang, J., Liu, Z., Chen, Y., Lu, B., He, H., Tang, S., Sun, Y., Liu, F., et al. (2019) · Journal of Biological Engineering · doi:10.1186/s13036-019-0189-9 · Cited by 211
Self-citationEngineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia
Gurbatri, C. R., Radford, G. A., Vrbanac, L., Im, J., Thomas, E. M., Coker, C., Taylor, S. R., Jang, Y., Sivan, A., Rhee, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44776-4 · Cited by 199
“…whether orally delivered E. coli Nissle 1917 (EcN) can selectively colonize adenomas and isolated neoplastic lesions in genetic, orthotopic, and transplant murine models of CRC. EcN is a probioticstrain with demonstrated safety and hasbeen investigatedas a chassis for other cancer types 26 – 28 .”
Tweak to Treat: Reprograming Bacteria for Cancer Treatment
Sieow, B. F.-L., Wun, K. S., Yong, W. P., Hwang, I. Y., & Chang, M. W. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2020.11.004 · Cited by 158
Xie, S., Zhao, L., Song, X., Tang, M., Mo, C., & Li, X. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.041 · Cited by 164
Insights from 100 years of research with probiotic E. coli
Wassenaar, T. M. (2016) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2016.00029 · Cited by 145
“, azurin) can enhance the effectivity of bacterial cancer treatment [103], while ferritin-overexpression provides a practical marker for tumor detection by magnetic resonance imaging (MRI) [104].”
BackgroundBioengineered Escherichia coli Nissle 1917 for tumour‐targeting therapy
Yu, X., Lin, C., Yu, J., Qi, Q., & Wang, Q. (2019) · Microbial Biotechnology · doi:10.1111/1751-7915.13523 · Cited by 159
“For example, the azurin protein was constitutively expressed to inhibit tumours (Zhang et al., 2012).”
BackgroundZhang, Y., Ji, W., Lian, H., Chen, Y., Ding, X., Sun, Y., Hu, S., Yang, H., Huang, W. T., Zhang, Y., et al. (2018) · Theranostics · doi:10.7150/thno.21575 · Cited by 121
Self-citationGenetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application
Ou, B., Yang, Y., Tham, W. L., Chen, L., Guo, J., & Zhu, G. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7829-5 · Cited by 114
“The tumor-targeting properties of EcN were employed to inhibit mouse B16 melanoma and 4T1 breast tumors by expressing the azurin protein in EcN (Zhang et al. 2012).”
BackgroundInfluentialBacteria and bacterial derivatives as delivery carriers for immunotherapy
Kang, S., Nguyen, D.-H., Yoo, S. W., & Min, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114085 · Cited by 106
Bacteria and genetically modified bacteria as cancer therapeutics: Current advances and challenges
Nallar, S. C., Xu, D.-Q., & Kalvakolanu, D. V. (2016) · Cytokine · doi:10.1016/j.cyto.2016.01.002 · Cited by 94
Dróżdż, M., Makuch, S., Cieniuch, G., Woźniak, M., & Ziółkowski, P. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118296 · Cited by 77
Emerging applications of bacteria as antitumor agents
Kalia, V. C., Patel, S. K. S., Cho, B., Wood, T. K., & Lee, J.-K. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.012 · Cited by 81
Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy
Li, R., Helbig, L., Fu, J., Bian, X., Herrmann, J., Baumann, M., Stewart, A. F., Müller, R., Li, A., Zips, D., et al. (2019) · Research in Microbiology · doi:10.1016/j.resmic.2018.11.001 · Cited by 73
Self-citationSalmonella and cancer: from pathogens to therapeutics.
Chorobik, P., Czaplicki, D., Ossysek, K., & Bereta, J. (2013) · Acta Biochimica Polonica · doi:10.18388/abp.2013_1984 · Cited by 68
Zhang, Y., Dang, M., Tian, Y., Zhu, Y., Liu, W., Tian, W., Su, Y., Ni, Q., Xu, C., Lu, N., et al. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b10840 · Cited by 69
Self-citationGenetically Engineered Microorganisms and Their Impact on Human Health
Mahdizade Ari, M., Dadgar, L., Elahi, Z., Ghanavati, R., & Taheri, B. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/6638269 · Cited by 67
Engineering of bacterial strains and their products for cancer therapy
Bernardes, N., Chakrabarty, A. M., & Fialho, A. M. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-4926-6 · Cited by 70
Bioluminescence Imaging Applications in Cancer: A Comprehensive Review
AlSawaftah, N., Farooq, A., Dhou, S., & Majdalawieh, A. F. (2020) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2020.2995124 · Cited by 72
Xie, S., Chen, M., Song, X., Zhang, Z., Zhang, Z., Chen, Z., & Li, X. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.07.041 · Cited by 63
Biosensing in Smart Engineered Probiotics
Rottinghaus, A. G., Amrofell, M. B., & Moon, T. S. (2020) · Biotechnology Journal · doi:10.1002/biot.201900319 · Cited by 67
Gao, M., Zhou, J., Su, Z., & Huang, Y. (2017) · Protein Science · doi:10.1002/pro.3310 · Cited by 64
“remarkably restrained and pulmonary metastasis was prevented in immunocompetent mice.(48) In the”
BackgroundLi, J., Sun, M., Liu, L., Yang, W., Sun, A., Yu, J., Liu, D., Zhao, W., Cheng, M., He, Z., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c02408 · Cited by 64
Bacteria-mediated cancer therapies: opportunities and challenges
Yang, M., Yang, F., Chen, W., Liu, S., Qiu, L., & Chen, J. (2021) · Biomaterials Science · doi:10.1039/d1bm00634g · Cited by 62
Engineered bacteria for near-infrared light-inducible expression of cancer therapeutics
Qiao, L., Niu, L., Wang, Z., Deng, Z., Di, D., Ma, X., Zhou, Y., Kong, D., Wang, Q., Yin, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00932-3 · Cited by 80
“39).”
Emerging clinical relevance of microbiome in cancer: promising biomarkers and therapeutic targets
Dai, J.-H., Tan, X.-R., Qiao, H., & Liu, N. (2023) · Protein & Cell · doi:10.1093/procel/pwad052 · Cited by 59
“…Nissle 1917 has been engineered as a targeted transport vector carrying anticancer genes to tumor hypoxic regions, such as tumor suppressor azurin (Zhang et al., 2012), p53, and/or anti-angiogenic factor Tum-5 (He et al., 2019), followed by high copy amplification and efficient expression of…”
BackgroundEscherichia coli Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth
Lian, H., Yang, H., Liu, F., Chen, Y., Tang, S., Ji, W., Tang, J., Liu, Z., Sun, Y., Hu, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20486 · Cited by 65
“Yunlei et al [29] used EcN as a delivery system for gene therapy on tumor-bearing mice.”
BackgroundSelf-citationMetabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors
Chiang, C., & Huang, P.-H. (2021) · Scientific Reports · doi:10.1038/s41598-021-85372-6 · Cited by 59
Quantifying and Engineering Mucus Adhesion of Probiotics
Mays, Z. J. S., Chappell, T. C., & Nair, N. U. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00356 · Cited by 62
Hypoxic Tumor Radiosensitization Using Engineered Probiotics
Huang, C., Wang, X., Liu, L., Jiang, W., Liu, W., Ma, W., & Zhao, H. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002207 · Cited by 59
Cell-penetrating peptides as a promising tool for delivery of various molecules into the cells
Ruczyński, J., Wierzbicki, P., Kogut-Wierzbicka, M., Mucha, P., Siedlecka-Kroplewska, K., & Rekowski, P. (2014) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.a2014.0034 · Cited by 52
“The most recent reports have suggested the selective uptake of azurin-based CPPs by breast cancer [78], melanoma [79] or lymphoma [80, 81] cells in vitro.”
BackgroundNative and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases
Shen, H., Zhao, Z., Zhao, Z., Chen, Y., & Zhang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020594 · Cited by 58
Huang, Y., Xiaojun, L., Yu, S., Chen, R., & Chen, W.-Z. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00314 · Cited by 59
Zhou, T., Wu, J., Tang, H., Liu, D., Jeon, B., Jin, W., Wang, Y., Zheng, Y., Khan, A., Han, H., et al. (2024) · npj Biofilms and Microbiomes · doi:10.1038/s41522-024-00479-8 · Cited by 55
“However, the vast majority of engineered bacteria are adopted constitutive expression systems to deliver payloads; Some payloads are toxic to normal cells 30 – 33 , which increases the exposure risk to non-targeted organs 23,34 .”
Bacterial proteins and peptides in cancer therapy: Today and tomorrow
Chakrabarty, A. M., Bernardes, N., & Fialho, A. M. (2014) · Bioengineered · doi:10.4161/bioe.29266 · Cited by 49
“Azurin has also been used in Escherichia coli Nissle 1917 cells through its hyper-expression in such cells to allow melanoma and breast tumor regression.(33) Similarly, azurin’s binding domain to EphB2 via its G-H loop region (azurin 88–113) has been used to enhance radiation sensitivity of lung tumor cells through co…”
MethodPotent and Tumor specific: Arming Bacteria With Therapeutic Proteins
Dessel, N. V., Swofford, C. A., & Forbes, N. S. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.113 · Cited by 53
Cross-talk between cancer and Pseudomonas aeruginosa mediates tumor suppression
Choi, J. K., Naffouje, S. A., Goto, M., Wang, J., Christov, K. T., Rademacher, D. J., Green, A., Stecenko, A. A., Chakrabarty, A. M., Gupta, T. K. D., et al. (2023) · Communications Biology · doi:10.1038/s42003-022-04395-5 · Cited by 51
In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy
Chiang, C., & Hong, Y.-H. (2021) · Scientific Reports · doi:10.1038/s41598-021-97457-3 · Cited by 47
Effendi, S. S. W., & Ng, I. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2109405 · Cited by 50
“Then, EcN was employed as an azurin carrier where azurin protein was generated with secretory signal peptide under the control of the modified lac promoter that continually releases and kills the tumor cells through apoptosis induction (Zhang et al. 2012).”
MethodTargeted delivery of nano-radiosensitizers for tumor radiotherapy
Shi, S., Zhong, H., Zhang, Y., & Mei, Q. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216101 · Cited by 45
Self-citationKocijancic, D., Leschner, S., Felgner, S., Komoll, R., Frahm, M., Pawar, V., & Weiß, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16906 · Cited by 44
“While successful clearance of RenCa may surely require supplementation in an extrinsic form [1, 5, 52, 53], the localized constant stimulation by persistent Salmonella sets it apart from single agent immune therapies externally delivered to the tumor.”
BackgroundProduction and Sensing of Butyrate in a Probiotic E. coli Strain
Bai, Y., & Mansell, T. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103615 · Cited by 47
Nguyen, C., & Nguyễn, V. D. (2016) · BioMed Research International · doi:10.1155/2016/8490482 · Cited by 43
“Even azurin has been overproduced in Escherichia coliNissle 1917 probiotic cells to allow the regression of melanoma and breast tumor in the mouse model [44].”
BackgroundAnticancer Actions of Azurin and Its Derived Peptide p28
Huang, F., Shu, Q., Qin, Z., Tian, J., Su, Z., Huang, Y., & Gao, M. (2020) · The Protein Journal · doi:10.1007/s10930-020-09891-3 · Cited by 45
Singh, A. K., Pandey, S., & Kumar, G. N. (2014) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12456 · Cited by 45
Reprogramming Synthetic Cells for Targeted Cancer Therapy
Lim, B., Yin, Y., Ye, H., Cui, Z., Papachristodoulou, A., & Huang, W. E. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00631 · Cited by 43
Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy
Shanmugaraj, B., Priya, L. B., Mahalakshmi, B., Subbiah, S., Hu, R., Velmurugan, B. K., & Baskaran, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117550 · Cited by 43
Chen, J., Li, X., Liu, Y., Su, T., Lin, C., Shao, L., Li, L., Li, W., Niu, G., Yu, J., et al. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13894 · Cited by 43
“Tumour growth and pulmonary metastasis are efficiently suppressed by azurin release, and the resulting inflammatory response does not cause significant toxicity (Zhang et al., 2012).”
BackgroundZainuddin, H. S., Bai, Y., & Mansell, T. J. (2019) · Engineering in Life Sciences · doi:10.1002/elsc.201900003 · Cited by 39
“These efforts include in situ secretion of antimicrobial peptides in the animal gut [12,13], therapeutic protein delivery [14,15], and heterologous expression of immunomodulatory molecules such as human α-defensin 5 (HD5), β-defensin 2 (HBD2) [16] and interleukin-10 [17] for ulcerative colitis treatment.”
BackgroundModulating tumor immunity using advanced microbiome therapeutics producing an indole metabolite
Vaaben, T. H., Lützhøft, D. O., Koulouktsis, A., Dawoodi, I. M., Stavnsbjerg, C., Kvich, L., Gögenür, I., Vazquez-Uribe, R., & Sommer, M. O. A. (2025) · EMBO Reports · doi:10.1038/s44319-025-00386-9 · Cited by 41
“…1917 (EcN) has been extensively investigated as a microbial vector for drug delivery and modulation of the tumor microenvironment across preclinical (Chowdhury et al, 2019; Stritzker et al, 2007; Tumas et al, 2023; Xie et al, 2017; Zhang et al, 2012) and clinical cancer research (Luke et al, 2023).”
Wu, J., Huang, H., Wang, L., Gao, M., Meng, S., Zou, S., Feng, Y., Feng, Z., Zhu, Z., Cao, X., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2316575 · Cited by 41
“19,20 23 Saccharomyces cerevisiae , which is used as a probiotic, serves as a platform for natural product synthesis and has extensive applications in the fields of food and medicine.”
BackgroundGenetically Engineered Bacterial Protein Nanoparticles for Targeted Cancer Therapy
Yang, H., Jiang, F., Ji, X., Wang, L., Wang, Y., Zhang, L., Tang, Y., Wang, D., Luo, Y., Li, N., et al. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s292432 · Cited by 39
“coli could colonize in tumor tissues but also the plasmid would not vanish for a short time in vivo.(51)”
BackgroundSonogenetics-controlled synthetic designer cells for cancer therapy in tumor mouse models
Gao, T., Niu, L., Wu, X., Dai, D., Zhou, Y., Liu, M., Wu, K., Yu, Y., Guan, N., & Ye, H. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101513 · Cited by 59
Engineered bacteria for augmented in situ tumor vaccination
Shen, X., Zhu, C., Liu, X., Zheng, H., Wu, Q., Xie, J., Huang, H., Liao, Z., Shi, J., Nan, K., et al. (2023) · Biomaterials Science · doi:10.1039/d2bm01593e · Cited by 38
Kocijancic, D., Felgner, S., Schauer, T., Frahm, M., Heise, U., Zimmermann, K., Erhardt, M., & Weiß, S. (2017) · Oncotarget · doi:10.18632/oncotarget.18392 · Cited by 37
Alizadeh, S., Esmaeili, A., & Omidi, Y. (2020) · PubMed Central · doi:10.22038/ijbms.2020.43016.10115 · Cited by 51
Tang, H., Zhou, T., Jin, W., Zong, S., Mamtimin, T., Salama, E., Jeon, B., Liu, P., Han, H., & Li, X. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121709 · Cited by 36
Yang, M., Conceição, M., Chen, W., Yang, F., Zhao, B., Wood, M. J. A., Qiu, L., & Chen, J. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.12.027 · Cited by 30
Triassi, A. J., Fields, B. D., Monahan, C. E., Means, J., Park, Y., Doosthosseini, H., Padmakumar, J. P., Isabella, V. M., & Voigt, C. A. (2023) · Cell Systems · doi:10.1016/j.cels.2023.05.004 · Cited by 33
Hersi, F., Elgendy, S. M., Shamma, S. A. A., Altell, R. T., Sadiek, O., & Omar, H. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120573 · Cited by 31
Bacteria-based nanodrug for anticancer therapy
Xie, Y., Huang, M., Li, D., Hou, J., Liang, H., Nasim, A. A., Huang, J., Xie, C., Leung, E. L., & Fan, X. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106282 · Cited by 29
Murine solid tumours as a novel model to study bacterial biofilm formation in vivo
Pawar, V., Crull, K., Komor, U., Kasnitz, N., Frahm, M., Kocijancic, D., Westphal, K., Leschner, S., Wolf, K., Loessner, H., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12258 · Cited by 28
Characterization of a Lactococcus lactis promoter for heterologous protein production
Ogaugwu, C., Cheng, Q., Fieck, A., Hurwitz, I., & Durvasula, R. V. (2017) · Biotechnology Reports · doi:10.1016/j.btre.2017.11.010 · Cited by 26
Bacteria-Based Live Vehicle for In Vivo Bioluminescence Imaging
Jiang, T., Yang, X., Li, G., Zhao, X., Sun, T., Müller, R., Wang, H., Li, M., & Zhang, Y. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c03568 · Cited by 28
Self-citationA molecular toolkit for heterologous protein secretion across Bacteroides species
Yeh, Y.-H., Kelly, V. W., Pour, R. R., & Sirk, S. J. (2024) · Nature Communications · doi:10.1038/s41467-024-53845-7 · Cited by 26
Using bugs as drugs: Administration of bacteria-related microbes to fight cancer
Wang, J., Ghosh, D., & Maniruzzaman, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114825 · Cited by 25
Bacteria-Based Nanoprobes for Cancer Therapy
Lu, Y., Mei, N., Ying, Y., Wang, D., Li, X., Zhao, Y., Zhu, Y., Shen, S., & Yin, B. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s438164 · Cited by 22
“121,122 Symbioflor-2, another probiotic E. coli strain, is also investigated for its antitumoral potency.”
BackgroundGentschev, I., Petrov, I. S., Ye, M., Kafuri, L., Toews, R., Cecil, A., Oelschaeger, T. A., & Szalay, A. A. (2022) · Cancers · doi:10.3390/cancers14246033 · Cited by 17
Sharma, D., Dhiman, I., Paul, S. D., Das, D. K., Das, D., Dash, S. K., & Pramanik, A. (2025) · ACS Omega · doi:10.1021/acsomega.5c02077 · Cited by 26
Engineered bacteria for cancer therapy: Advancements, challenges, and future directions
Wang, M.-G., Liu, M., Wang, D., Yang, D., Zeng, Y., Lan, Y., & Wang, Q. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003807 · Cited by 19
“[132] Apoptin, another apoptosis-inducing protein derived from the chicken anemia virus, selectively induces apoptosis in a wide range of human cancer cell lines through a p53-independent, Bcl-2-insensitive mechanism, without affecting normal tissues.”
Heterologous expression of azurin from Pseudomonas aeruginosa in the yeast Pichia pastoris
Ünver, Y., Gün, B. Ş., Acar, M., & Arslan, Ş. Y. (2020) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2020.1855444 · Cited by 18
“They concluded that thanks to azurin expression, B16 melanoma, and orthotopic 4T1 breast tumor growth were inhibited in mice.([62])”
BackgroundAnticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment
Sood, A., Jothiswaran, V. V., Singh, A., & Sharma, A. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00264 · Cited by 20
The Role of Hitchhiking in Cancer Therapeutics—A Review
Padmakumar, A., Koyande, N. P., & Rengan, A. K. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200042 · Cited by 20
Towards Understanding Tumour Colonisation by Probiotic Bacterium E. coli Nissle 1917
Radford, G., Vrbanac, L., de Nys, R., Worthley, D. L., Wright, J. A., Hasty, J., & Woods, S. L. (2024) · Cancers · doi:10.3390/cancers16172971 · Cited by 21
“The presence of E. coli , specifically EcN [12] and K-12 [98], in the tumour transition zone also reportedly led to increased necrosis [12,98], possibly as a result of upregulation of TNF-α leading to tumour cell apoptosis and decreased blood vessels within the region [98].”
BackgroundInfluentialFrom promotion to management: The wide impact of bacteria on cancer and its treatment
Peréz-Chanona, E., & Jobin, C. (2014) · BioEssays · doi:10.1002/bies.201400015 · Cited by 13
“coli NISSLE 1917, a well documented probiotic used to alleviate diarrhea and intestinal inflammation in patients with IBD, has recently been shown to reduce tumor volume of breast tumor-bearing mice [28].”
BackgroundYuan, S., Yang, X., Bremmer, A., Wang, Y., Li, S., Chen, Y., You, Y., & Hu, Q. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2507711122 · Cited by 13
“Tumors’ abnormal vasculature with enhanced permeability facilitates bacterial extravasation and trapping (42).”
Sarate, P., Šrůtková, D., Geissler, N., Schwarzer, M., Schabussová, I., Inić‐Kanada, A., Kozáková, H., & Wiedermann, U. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612775 · Cited by 13
Breast cancer vaccination: Latest advances with an analytical focus on clinical trials
Vajari, M. K., Sanaei, M., Salari, S., Rezvani, A., Ravari, M. S., & Bashash, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110696 · Cited by 10
Li, H., Zhou, Y. Q., & Ye, B. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00570 · Cited by 12
Huang, F., Tang, J., Lian, H., Ding, X., Huang, S., Zhang, Y., Sun, Y., & Xia, L. (2018) · Microbial Cell Factories · doi:10.1186/s12934-018-0859-1 · Cited by 10
“Standard hematoxylin and eosin (HE) staining procedures were employed for morphological assessment [30].”
MethodSelf-citationBacteria−Based Synergistic Therapy in the Backdrop of Synthetic Biology
Bao, Y., Cheng, Y., Liu, W., Luo, W., Zhou, P., & Qian, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.845346 · Cited by 10
“Pulmonary metastasis was prevented (82)”
Kiaheyrati, N., Babaei, A., Ranji, R., Bahadoran, E., Taheri, S., & Farokhpour, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122734 · Cited by 12
Chen, H., Fang, Q., Tu, Q., Liu, C., Yin, J., Yin, Y., Xia, L., Bian, X., & Zhang, Y. (2018) · FEMS Microbiology Letters · doi:10.1093/femsle/fny102 · Cited by 10
Self-citationJanosch, D., Dubbert, S., Eiteljörge, K., Diehl, B. W. K., Sonnenborn, U., Passchier, L. V., Wassenaar, T. M., & von Bünau, R. (2019) · Beneficial Microbes · doi:10.3920/bm2018.0113 · Cited by 10
Feng, J., Liu, Y., Pan, X., Jin, F., Wu, L., Chen, J., Wan, B., Zhang, X., Rodrigues, L. R., & Zhang, Y. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c08684 · Cited by 8
Self-citationApplication of Bacterial Whole-Cell Biosensors in Health
Song, Y., Rampley, C. P. N., Chen, X., Du, F., Thompson, I. P., & Huang, W. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-23217-7_136 · Cited by 10
Li, X., Hua, D., Wu, D., Hong, W., Kang, Y., Tang, L., Yang, Q., Wang, X., Li, B., Li, R., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70987 · Cited by 8
Application of Antimicrobial Peptides in the Design and Production of Anticancer Agents
Vakili, B., & Jahanian‐Najafabadi, A. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10501-w · Cited by 6
A novel tumor-targeting strain of Xenorhabdus stockiae exhibits potent biological activities
Zhang, C., Chen, H., Hüttel, S., Hu, S., Zhang, W., Ding, X., Yin, J., Yin, Y., Müller, R., Xia, L., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.984197 · Cited by 8
“typhimurium, Escherichia coli Nissle 1917, and Bifidobacterium, can efficiently colonize and proliferate in certain tumors, resulting in the suppression of tumor growth (Tang et al., 2009; Yu et al., 2012; Zhang et al., 2012; Roberts et al., 2014).”
BackgroundSelf-citationGradient Magnetic Field Accelerates Division of E. coli Nissle 1917
Gorobets, S., Gorobets, O., Sharai, I., Polyakova, T., & Zablotskii, V. (2023) · Cells · doi:10.3390/cells12020315 · Cited by 8
Current and emerging approaches to manage chronic inflammatory gut disorders
Green, K. M., Shin, S., Jha, R. K., & Kumar, A. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1762119 · Cited by 5
“EcN is the only well-established Gram-negative probiotic bacterium, known for being easily manipulated, transformed, and cultured, with proven safety and robust colonization potential (Scaldaferri et al., 2016; Zhang et al., 2012; Secher et al., 2017; Danino et al., 2015).”
Rise of Bacterial Small Proteins and Peptides in Therapeutic Applications
Meenakshi, S., & Shelin, R. (2023) · Protein and Peptide Letters · doi:10.2174/0929866530666230118144723 · Cited by 5
Application of Bacterial Whole-Cell Biosensors in Health
Song, Y., Rampley, C. P. N., Chen, X., Du, F., Thompson, I. P., & Huang, W. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-47405-2_136-1 · Cited by 4
Hung, J. J.-C., Tsai, T. P., & Lan, E. I. (2026) · Fermentation · doi:10.3390/fermentation12060265 · Cited by 4
Metadata
- Authors
- Zhang, Y., Zhang, Y., Xia, L., Zhang, X., Ding, X., Yan, F., & Wu, F.
- Affiliations
- Hunan Normal University (CN)
- College of Life Science, Hunan Provincial Key Laboratory of Microbial Molecular Biology—State Key Laboratory Breeding Base of Microbial Molecular Biology, Hunan Normal University, Changsha, China
- Venue
- Applied and Environmental Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2012-11
- Volume
- 78
- Issue
- 21
- Pages
- 7603-7610
- ISSN
- 0099-2240 (ISSN-L)
- 1098-5336
- PMC
- PMC3485711
- OpenAlex
- W1964108510
- Cited by
- 138
- References
- 46
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 14 · 2023: 12 · 2022: 16 · 2021: 15 · 2020: 18 · 2019: 6 · 2018: 8 · 2017: 8 · 2016: 4 · 2015: 2 · 2014: 5 · 2013: 2
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Applied and Environmental Microbiology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- Escherichia coli Nissle 1917, azurin, tumor-targeting bacteria, B16 melanoma, 4T1 breast cancer, tumor growth inhibition, lung metastasis, neutrophils, lymphocytes, inflammation, bacterial drug delivery, cancer therapy, recombinant protein expression
- MeSH terms
- Animals, Antineoplastic Agents, Azurin, Disease Models, Animal, Escherichia coli, Female, Genetic Engineering, Lung Neoplasms, Mammary Neoplasms, Experimental, Melanoma, Experimental, Mice, Inbred BALB C, Plasmids, Drug Delivery Systems, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.